A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Conditions

• Advanced/Metastatic Solid Tumors
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal-junction Cancer
• HNSCC
• Head and Neck Squamous Cell Carcinoma
• NSCLC

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• MCLA-158 — DRUG
  full-length IgG1 bispecific antibody targeting EGFR and LGR5
• MCLA-158 + Pembrolizumab — COMBINATION_PRODUCT
  MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
• MCLA-158 + FOLFIRI — COMBINATION_PRODUCT
  MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
• MCLA-158 + FOLFOX — COMBINATION_PRODUCT
  MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.

Study Details

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.

Key Dates

First listed

May 16, 2018

Start date

May 2, 2018

Status verified

Jul 2026

Primary completion

May 31, 2028

Completion

Nov 30, 2028

Study Design

Enrollment

560 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: MCLA-158 (Single-Agent)
  In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion (i.v.) of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days. In addition, in the expansion phase, one randomized cohort will evaluate 2 doses (1100 mg and 1500 mg) of MCLA-158 in head and neck squamous cell carcinoma patients. Also in the expansion phase, a subcutaneous formulation of MCLA-158 will be evaluated.
• Experimental: MCLA-158 + Pembrolizumab
  MCLA-158 in combination with pembrolizumab will be explored first in head and neck squamous cell carcinoma patients eligible to receive pembrolizumab as first-line monotherapy.
• Experimental: MCLA-158 + FOLFIRI combination chemotherapy
  MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
• Experimental: MCLA-158 + FOLFOX combination chemotherapy
  MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.

Primary Outcome Measure

Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1 [ Time Frame: 4 weeks ]

Central Contacts

• Silke Thiele, MD
  +31 85 016 2500
  [email protected]
• Eduardo Pennella, MD
  +1 617 401 4499
  [email protected]

Locations (31)

Find similar trials in La Jolla, CA

Related Studies

• Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Esophageal Cancer Risk Registry
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
  Recruiting · University of Colorado, Denver · Aurora, Colorado